Analyst Research Report Snapshot

Title:

BTG - IN THE SAME VEIN

Price:

$10.00

Provider:

Edison Investment Research

Date:

13 Dec 2013

Pages:

12

Type:

AcrobatPDF

Companies referenced:

BTG.L JNJ.N MDVN.OQ SASY.PA SRX.AX

Available for Immediate Download
Summary:

US approval for Varithena represents another inflection point for BTG’s Interventional Medicine (IM) business. Four commercial-stage products, which target the fast-growing interventional oncology and vascular markets, could take IM sales to c £390m by FY20. Our revised valuation of £2.2bn (606p/share) could rise to £2.3bn with pipeline success. Marketed assets plus Varithena are worth up to 564p, implying downside protection.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.